Literature DB >> 34926767

Poroid hidradenocarcinoma and atypical hidradenoma papilliferum of the vulva - Two cases.

Monica F G McGauran1, Tom Manolitsas2,3, Bassam Tawfik4, Dhaval Joshi4, Julie M Lamont1,5.   

Abstract

Benign and malignant tumours may arise from eccrine and apocrine sweat glands. Hidradenocarcinoma is a rare malignant eccrine sweat gland tumour representing <0.01% of all skin cancers. There are 6 case reports in the literature of hidradenocarcinoma arising on the vulva, none of which are classified as poroid hidradenocarcinoma. Hidradenocarcinoma is thought to be an aggressive tumour with poor prognosis and high levels of local recurrence and systemic metastases. Conversely, hidradenoma papilliferum is a common benign apocrine sweat gland tumour found on the vulva. The prevalence and significance of atypical changes, however, is unknown. Distinguishing between these tumour types can be difficult. The authors present two cases, a poroid hidradenocarcinoma and an atypical hidradenoma papilliferum with necrosis and increased mitotic activity, to illustrate the diagnostic challenges associated with rare tumours of the vulva in the absence of an established histopathological classification system.
© 2021 The Author(s).

Entities:  

Keywords:  Dermatopathology; Hidradenocarcinoma; Hidradenoma papilliferum; Sweat gland carcinoma; Vulva

Year:  2021        PMID: 34926767      PMCID: PMC8651789          DOI: 10.1016/j.gore.2021.100886

Source DB:  PubMed          Journal:  Gynecol Oncol Rep        ISSN: 2352-5789


Introduction

Cutaneous sweat gland tumours are uncommon and may be of eccrine or apocrine origin (Obaidat et al., 2007). Eccrine sweat glands are abundant and can be found all over the body, producing mostly sweat. Apocrine sweat glands are associated with hair follicles and found in the axillae, anogenital region, around the nipple and eye lid. They secrete a thicker fat droplet filled fluid which can mix with surface bacteria to produce body odour. Benign and malignant neoplasms can develop in both eccrine and apocrine sweat glands. Examples of benign eccrine neoplasms include poroma, hidradenoma, spiradenoma, cylindroma and syringoma, with porocarcinoma, hidradenocarcinoma, spiradenocarcinoma, malignant cylindroma and syringoid carcinoma representing their malignant counterparts (Obaidat et al., 2007). Examples of benign apocrine neoplasms include syringocystadenoma papilliferum and hidradenoma papilliferum, with syringocystadenocarcinoma and apocrine carcinoma representing their malignant counterparts (Obaidat et al., 2007). Malignant sweat gland tumours of the vulva are very rare. Diagnosis, management and prognosis are poorly understood and most evidence has been derived from case reports and case series (Kazakov et al., 2011). Hidradenocarcinoma may also be referred to as malignant clear cell myoepithelioma, malignant acrospiroma, clear cell hidradenocarcinoma, malignant eccrine carcinoma, malignant clear cell hidradenoma, and primary mucoepidermoid cutaneous carcinoma. Hidradenocarcinomas account for <0.001% of all tumours and <0.01% of all skin cancers (Soni et al., 2015) and represent 1/13,000 tumours received by a major dermatopathology laboratory (Aziz et al., 2020). Six case reports have been identified in the literature of hidradenocarcinoma arising on the vulva (Messing et al., 1993, Massad et al., 1996, Smith and DeSimone, 2021, Kim et al., 2021, Wick et al., 1985, Giannelli et al., 2017). Hidradenocarcinoma often presents as a painless papule or nodule with slow clinical evolution (Wick et al., 1985) and are therefore rarely suspected clinically. Diagnosis of hidradenocarcinoma is challenging due to a wide spectrum of histopathological features that have been described and no established classification system in existence (Aziz et al., 2020) In addition, while accepted histological criteria are reported, not all lesions will possess all the criteria (Nazarian et al., 2009). Five-year survival for hidradenocarcinoma is reported between 30% (Avraham et al., 2013) and 73.9% (Avraham et al., 2013). Local recurrence after surgery has been reported at 50% (Moore et al., 2021). It is, therefore, an important diagnosis to make so that appropriate treatment and surveillance can be undertaken. Hidradenoma papillipferum is a benign apocrine neoplasm involving anogenital mammary like glands and commonly occurs on the vulva, most commonly on the inner aspect of the labia (Sington et al., 2006). Malignant transformation is very rare. Benign tumours with atypical features have been described in the literature (Sington et al., 2006) but the clinical course and long-term outcomes are poorly understood. We present two cases, one of a poroid hidradenocarcinoma of the vulva, and one of hidradenoma papilliferum with increased mitotic activity and necrosis, possibly representing carcinoma in situ, to illustrate pathological features which contribute to a diagnosis of a malignant sweat gland tumour and associated diagnostic challenges.

Case report

Case 1: Poroid hidradenocarcinoma

A 52-year-old female presented with an itchy, ulcerating, papular lesion on her right labia majora that had been present for 2 years. An excisional biopsy was performed. Histopathology demonstrated a hidradenocarcinoma arising within a poroid hidradenoma with the closest margin 0.1 mm. The lesion was characterised by ulceration, necrosis, and cells with pleomorphic nuclei and mitotic activity. One area of the tumour had cells with cytoplasmic vacuoles and this area stained positively for CK7, supporting the presence of ductal differentiation and the diagnosis of a primary cutaneous adnexal neoplasm (Qureshi et al., 2004), and BerEP4, which is commonly expressed in sweat gland tumours and in particular, in porocarcinomas (Afshar et al., 2013). The patient was referred to a Gynaecological Oncologist who performed a wide local excision of the scar. No residual malignancy or hidradenoma was identified. There was been no evidence of recurrence or metastatic disease after 9 months of observation (Fig. 1, Fig. 2).
Fig. 1

Case 1 – Areas of atypia within the tumour including cells with pleomorphic nuclei, multiple mitotic figures and areas of necrosis.

Fig. 2

Case 1 – Immunohistochemistry: CK7 shows positive staining in the lumina of vacuolated cells.

Case 1 – Areas of atypia within the tumour including cells with pleomorphic nuclei, multiple mitotic figures and areas of necrosis. Case 1 – Immunohistochemistry: CK7 shows positive staining in the lumina of vacuolated cells.

Case 2: Hidradenoma papilliferum with possible carcinoma in situ

A 54-year-old female presented with a persistent lesion on her right posterior vulva. An excisional biopsy was performed. Histopathology was initially reported as hidradenocarcinoma with close margins. The patient was referred to a Gynaecological Oncologist and underwent a pelvic ultrasound which demonstrated no concerning features and a PET scan which demonstrated no FDG avid lymph nodes, locoregional or metastatic disease. A specialist histopathology review was conducted, and the diagnosis revised to hidradenoma pepilliferum with increased mitotic activity and necrosis (possibly carcinoma in situ) due to the absence of significant pleomorphism and stromal invasion. A wide local excision of the scar was performed. No residual malignancy or hidradenoma was identified (Fig. 3, Fig. 4).
Fig. 3

Case 2 – Round to ovoid and minimally pleomorphic cells with increased mitotic activity.

Fig. 4

Case 2 – High power view of central necrosis.

Case 2 – Round to ovoid and minimally pleomorphic cells with increased mitotic activity. Case 2 – High power view of central necrosis.

Discussion

Hidradenocarcinoma

Diagnosis of hidradenocarcinoma is challenging due to a wide spectrum of histopathological features that have been described and no established classification system in existence (Aziz et al., 2020). In addition, there is a wide range of differential diagnoses including atypical hidradenoma, eccrine porocarcinoma, clear cell neoplasms and squamous cell carcinoma (Jinnah et al., 2016). Features consistent with a diagnosis of hidradenocarcinoma include loss of circumscription, infiltration and deep extension, nuclear pleomorphism, increased mitotic activity, necrosis, perineural and vascular invasion. Not all tumours possess all the features listed, making the diagnosis challenging. In a study by Nazarian et al. (2009), all tumours with ≥3 of these features were classified as malignant. Due to the very limited data available, the prognostic significance of histopathological features is poorly understood. The authors suggest, however, that metastasising hidradenocarcinomas were more likely to be larger in size and demonstrate vascular invasion (Nazarian et al., 2009). The tumour presented in Case 1 demonstrates nuclear pleomorphism, increased mitotic activity and necrosis in keeping with a diagnosis of malignant hidradenocarcinoma. Features traditionally consistent with increased risk of metastasis such as perineural and vascular invasion, infiltration and deep extension are absent. It should be noted that an infiltrative growth pattern is not always seen with hidradenocarcinoma (Obaidat et al., 2007). Immunohistochemistry usually demonstrates positivity for cytokeratins (CK7), carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA) and S100 protein (Soni et al., 2015, Emanuel, xxxx).

Poroid hidradenoma

Poroid hidradenoma, such as that within which the hidradenocarcinoma evolved in Case 1, is a rare benign eccrine sweat gland neoplasm (Lim et al., 2021). Poroid hidradenomas account for approximately 5% of hidradenomas (Lim et al., 2021) and demonstrate differentiation towards the intradermal portion of the sweat gland (Lim et al., 2021, Macagno et al., 2021). No accounts of poroid hidradenomas arising on the vulva were found in the literature, with most cases arising on the trunk, upper limb, lower limb and head and neck (Lim et al., 2021). Treatment of poroid hidradenoma is excision and recurrence after excision has rarely been reported (Lim et al., 2021).

Atypical hidradenoma papilliferum

Hidradenoma papilliferum is a benign lesion of apocrine sweat glands most commonly found on the vulva and perianal region. It is understood that hidradenocarcinoma papilliferum or apocrine carcinoma does present with mitotic activity, necrosis and nuclear atypia (Obaidat et al., 2007). Little is known about those hidradenoma papilliferum which demonstrate atypical features. Nazarian et al. (2009) also describe the challenge posed by benign hidradenomas with focal atypical features such as that presented in Case 2. No follow up data has been reported on these patients but there is concern regarding possible recurrence risk and increased malignant potential (Nazarian et al., 2009). Sington et al. (2006) discuss cases of hidradenoma papilliferum that show pleomorphism. In a case series of 19, they found that nuclear abnormalities did not predict malignant behaviour. Features reported in the literature to be associated with hidradenocarcinoma papilliferum or apocrine carcinoma include infiltrative growth pattern, prominent cytologic atypia, solid sheets of cells and cribriform structures. There are too few cases, however, to provide definitive criteria (Sington et al., 2006). Vazmitel et al. (2008) describe a case of ductal carcinoma in situ (DCIS) arising in hidradenoma papilliferum. The features of the focal DCIS demonstrated crowded pleomorphic epithelial cells, hyperchromatic nuclei imparting a blastic appearance and atypical mitotic figures.

Management challenges

While the diagnosis of hidradenocarcinoma remains difficult to make, the management of hidradenocarcinoma also poses challenges. There is no specific staging system for cutaneous adnexal carcinomas therefore they are staged similarly to basal and squamous cell cancers (Avraham et al., 2013). There is no consensus regarding the management of hidradenocarcinoma. Lymph node sampling is recommended by some due to the anecdotally high rate of regional lymph node metastases (Ambe and Sondak, 2014), however a population database study showed nodal staging was rarely undertaken and did not demonstrate decreased survival associated with positive lymph nodes (Avraham et al., 2013). Wide local excision is regarded to be the mainstay of treatment (Avraham et al., 2013). There are case reports where radiation has been used successfully (Giannelli et al., 2017), however no difference in overall survival between those who had surgical excision and those who had surgery and adjuvant radiation was found in a population database study (Avraham et al., 2013). Chemotherapy has also been used to treat metastatic hidradenocarcinoma, with 5-FU and Capecitabine being examples of agents used successfully (Lerner et al., 2011). As outlined, malignant potential and risk of recurrence is not well understood in the case of hidradenoma papilliferum with atypical features. Excision is the mainstay of management.

Conclusion

Sweat gland neoplasms are found on the vulva and in cases where malignant transformation has occurred, or atypical features are present, insufficient evidence poses challenges in both diagnosis and management. Multidisciplinary histopathology review and discussion must be undertaken to optimise histopathological diagnosis and management in cases where these diagnoses are suspected. In addition, cases should, where possible, be contributed to the literature to increase our understanding of the disease.

Informed consent

Informed consent was obtained from the patients in both cases presented in this paper.

Author contribution

All authors contributed to the conception of this paper. MM wrote the initial draft of the manuscript and undertook the literature review. TM provided case information for case two and reviewed and made changes to the manuscript. BT provided case information for case one and reviewed and made changes to the manuscript. DJ provided case information for case two and reviewed and made changes to the manuscript. JL provided case information for case one and reviewed and made changes to the manuscript.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
  20 in total

1.  Complete response of metastatic malignant hidradenocarcinoma to capecitabine treatment.

Authors:  Adam Lerner; Angela Beckford; Steve Ugent; Lynne Goldberg; Scharukh Jalisi; Marie-France Demierre
Journal:  Arch Dermatol       Date:  2011-08

Review 2.  Metastatic clear cell eccrine hidradenocarcinoma of the vulva: survival after primary surgical resection.

Authors:  L S Massad; P Bitterman; D L Clarke-Pearson
Journal:  Gynecol Oncol       Date:  1996-05       Impact factor: 5.482

3.  Vulvar sweat gland carcinomas.

Authors:  M R Wick; J R Goellner; J T Wolfe; W P Su
Journal:  Arch Pathol Lab Med       Date:  1985-01       Impact factor: 5.534

4.  Poroid Hidradenocarcinoma of the Ankle: Case Report of a Rare Malignant Cutaneous Adnexal Neoplasm.

Authors:  Keith T Aziz; Adam S Levin; Jonathan D Cuda; James R Ficke
Journal:  J Foot Ankle Surg       Date:  2020 Mar - Apr       Impact factor: 1.286

Review 5.  Lesions of anogenital mammary-like glands: an update.

Authors:  Dmitry V Kazakov; Dominic V Spagnolo; Denisa Kacerovska; Michal Michal
Journal:  Adv Anat Pathol       Date:  2011-01       Impact factor: 3.875

6.  Poroid Hidradenoma: A Two-Case Report and Literature Review.

Authors:  Joon Soo Lim; Eun Sun Kwon; Ki Bum Myung; Seung Hyun Cheong
Journal:  Ann Dermatol       Date:  2021-05-04       Impact factor: 1.444

7.  Hidradenoma papilliferum with a ductal carcinoma in situ component: case report and review of the literature.

Authors:  Marina Vazmitel; Dominic V Spagnolo; Jana Nemcova; Michal Michal; Dmitry V Kazakov
Journal:  Am J Dermatopathol       Date:  2008-08       Impact factor: 1.533

8.  Vulvar apocrine hidradenocarcinoma arising in a hidradenoma papilliferum-A case report.

Authors:  Grace Y Kim; Malvika H Solanki; Ruifeng Guo
Journal:  J Cutan Pathol       Date:  2021-05-09       Impact factor: 1.587

Review 9.  Current management approach to hidradenocarcinoma: a comprehensive review of the literature.

Authors:  Abhishek Soni; Nupur Bansal; Vivek Kaushal; Ashok Kr Chauhan
Journal:  Ecancermedicalscience       Date:  2015-03-19

10.  Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy: a case report.

Authors:  Flavio Giannelli; Ilaria Chiola; Liliana Belgioia; Stefania Garelli; Alice Pastorino; Michela Marcenaro; Serafina Mammoliti; Sergio Costantini; Nicolò Bizzarri; Valerio Vellone; Salvina Barra; Renzo Corvò
Journal:  J Contemp Brachytherapy       Date:  2017-12-30
View more
  1 in total

1.  Hidradenocarcinoma of the Left Knee in a 55-Year-Old Woman: A Case Report.

Authors:  Muhammad Abu Zar Ghaffari; Faraz Saleem; Faiqa Zahoor; Saima Batool; Usman Ismail; Muhammad Usman; Hafiz Fahad Ullah Saeed
Journal:  Cureus       Date:  2022-07-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.